MediGene’s ‘Airbag’ Equity Deal Provides EndoTAG-1 Partnering Flexibility
This article was originally published in The Pink Sheet Daily
Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.
You may also be interested in...
For just under €10 million, Germany’s Medigene completes its restructuring with immunotherapy platform technologies that include dendritic cell vaccines, T-cell receptor based products and anti-T-cell monoclonal antibodies.
Talked up as a potential blockbuster, RhuDex produced positive Phase IIa findings a month earlier.
German firm also studies anti-angiogenesis drug in hormone-resistant breast cancer.